Johnson & Johnson Basic EPS 2012-2026 | JNJ
Johnson & Johnson annual/quarterly basic eps history and growth rate from 2012 to 2026. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
- Johnson & Johnson basic eps for the quarter ending March 31, 2026 was $0.00, a 100% decline year-over-year.
- Johnson & Johnson basic eps for the twelve months ending March 31, 2026 was $6.56, a 27.59% decline year-over-year.
- Johnson & Johnson annual basic eps for 2025 was $0.011B, a 90.58% increase from 2024.
- Johnson & Johnson annual basic eps for 2024 was $0.006B, a 57.93% decline from 2023.
- Johnson & Johnson annual basic eps for 2023 was $0.014B, a 103.22% increase from 2022.
| Johnson & Johnson Annual Basic EPS | |
|---|---|
| 2025 | $11.13 |
| 2024 | $5.84 |
| 2023 | $13.88 |
| 2022 | $6.83 |
| 2021 | $7.93 |
| 2020 | $5.59 |
| 2019 | $5.72 |
| 2018 | $5.70 |
| 2017 | $0.48 |
| 2016 | $6.04 |
| 2015 | $5.56 |
| 2014 | $5.80 |
| 2013 | $4.92 |
| 2012 | $3.94 |
| 2011 | $3.54 |
| Johnson & Johnson Quarterly Basic EPS | |
|---|---|
| 2026-03-31 | |
| 2025-12-31 | $2.12 |
| 2025-09-30 | $2.14 |
| 2025-06-30 | $2.30 |
| 2025-03-31 | $4.57 |
| 2024-12-31 | $1.42 |
| 2024-09-30 | $1.12 |
| 2024-06-30 | $1.95 |
| 2024-03-31 | $1.35 |
| 2023-12-31 | $1.61 |
| 2023-09-30 | $10.32 |
| 2023-06-30 | $1.98 |
| 2023-03-31 | $-0.03 |
| 2022-12-31 | $1.34 |
| 2022-09-30 | $1.70 |
| 2022-06-30 | $1.83 |
| 2022-03-31 | $1.96 |
| 2021-12-31 | $1.81 |
| 2021-09-30 | $1.39 |
| 2021-06-30 | $2.38 |
| 2021-03-31 | $2.35 |
| 2020-12-31 | $0.66 |
| 2020-09-30 | $1.35 |
| 2020-06-30 | $1.38 |
| 2020-03-31 | $2.20 |
| 2019-12-31 | $1.53 |
| 2019-09-30 | $0.67 |
| 2019-06-30 | $2.11 |
| 2019-03-31 | $1.41 |
| 2018-12-31 | $1.13 |
| 2018-09-30 | $1.47 |
| 2018-06-30 | $1.47 |
| 2018-03-31 | $1.63 |
| 2017-12-31 | $-3.97 |
| 2017-09-30 | $1.40 |
| 2017-06-30 | $1.42 |
| 2017-03-31 | $1.63 |
| 2016-12-31 | $1.40 |
| 2016-09-30 | $1.56 |
| 2016-06-30 | $1.46 |
| 2016-03-31 | $1.62 |
| 2015-12-31 | $1.17 |
| 2015-09-30 | $1.21 |
| 2015-06-30 | $1.63 |
| 2015-03-31 | $1.55 |
| 2014-12-31 | $0.91 |
| 2014-09-30 | $1.69 |
| 2014-06-30 | $1.53 |
| 2014-03-31 | $1.67 |
| 2013-12-31 | $1.25 |
| 2013-09-30 | $1.06 |
| 2013-06-30 | $1.36 |
| 2013-03-31 | $1.25 |
| 2012-12-31 | $0.92 |
| 2012-09-30 | $1.08 |
| 2012-06-30 | $0.51 |
| 2012-03-31 | $1.43 |
| 2011-12-31 | $0.09 |
| 2011-09-30 | $1.17 |
| 2011-06-30 | $1.01 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |